ConductScience.org, home

Comparison · NCT03640949-8babbc47

Vasopressin and Methylprednisolone vs Placebo: Number of Participants With Return of Spontaneous Circulation

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Vasopressin and Methylprednisolone vs Placebo: Number of Participants With Return of Spontaneous Circulation. Trial comparisons, record NCT03640949-8babbc47. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03640949-8babbc47

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4220.3610.486wilson
Risk in group 20.3260.2720.384wilson
Risk difference, group 1 minus group 20.09620.01140.179newcombe hybrid score
Risk ratio, group 1 over group 21.31.031.63log
Odds ratio, group 1 over group 21.511.052.17log
Number needed to treat, for one more participant with the outcome on Vasopressin and Methylprednisolone than on Placebo10.45.5787.4from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Vasopressin and Methylprednisolone
The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).~Vasopressin, Arginine: 20 IE of vasopressin per dose for a maximum of four doses (80 IU)~Methylprednisolone: 40 mg methylprednisolone once
100237OG000
Group 2Placebo
The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.~NaCl: Placebo
86264OG001

Outcome

Type
PRIMARY
Title
Number of Participants With Return of Spontaneous Circulation
Description
Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes
Time frame
During the cardiac arrest, an average of 20 minutes
Population

Source ClinicalTrials.gov

Trial

Title
Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
NCT number
NCT03640949
Phases
PHASE2, PHASE3
Conditions
Heart Arrest
Interventions
Vasopressin, Arginine, Methylprednisolone, NaCl
Lead sponsor
Lars Wiuff Andersen
Results first posted
2022-01-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03640949-8babbc47